The analysis focused only on CSNK1A1, CSNK1D, and CSNK1E, not on CSNK1G; CSNK1A1 alterations are dominant in clear cell renal cell carcinoma, and pancreas cancer, CSNK1D in liver and sarcoma, and CSNK1E in melanoma and liver. This evidence concerns the gene CSNK1D and pancreatic neoplasm.